Brittany Bagley Sells 3,400 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CFO Brittany Bagley sold 3,400 shares of the business’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the sale, the chief financial officer now owns 131,833 shares in the company, valued at $92,283,100. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $728.39 on Friday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $56.71 billion, a P/E ratio of 188.21, a P/E/G ratio of 5.17 and a beta of 1.24. The business has a fifty day simple moving average of $580.48 and a 200-day simple moving average of $591.44. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $732.22.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. Equities research analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Craig Hallum cut Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Finally, JMP Securities reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $652.73.

Institutional Trading of Axon Enterprise

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Geode Capital Management LLC boosted its position in Axon Enterprise by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after purchasing an additional 65,097 shares during the period. Capital World Investors boosted its stake in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after purchasing an additional 841,772 shares during the period. Alliancebernstein L.P. grew its stake in shares of Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.